Dilmapimod

CAS No. 444606-18-2

Dilmapimod( SB-681323 | GW 681323 )

Catalog No. M24403 CAS No. 444606-18-2

Dilmapimod is a potent inhibitor of p38 MAPK ,it potentially suppresses inflammation in chronic obstructive pulmonary disease.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
1 mL x 10 mM in DMSO 41 In Stock
5MG 37 In Stock
10MG 61 In Stock
25MG 116 In Stock
50MG 184 In Stock
100MG 343 In Stock
200MG Get Quote In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    Dilmapimod
  • Note
    Research use only, not for human use.
  • Brief Description
    Dilmapimod is a potent inhibitor of p38 MAPK ,it potentially suppresses inflammation in chronic obstructive pulmonary disease.
  • Description
    Dilmapimod is a potent inhibitor of p38 MAPK ,it potentially suppresses inflammation in chronic obstructive pulmonary disease.
  • In Vitro
    Dilmapimod (SB-681323) potently inhibits p38 MAPK signaling, measured by inhibition of sorbitol-induced pHSP27 expression.
  • In Vivo
    ——
  • Synonyms
    SB-681323 | GW 681323
  • Pathway
    Autophagy
  • Target
    Autophagy
  • Recptor
    Autophagy|p38 MAPK
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    444606-18-2
  • Formula Weight
    456.42
  • Molecular Formula
    C23H19F3N4O3
  • Purity
    >98% (HPLC)
  • Solubility
    DMSO:125 mg/mL (273.87 mM; Need ultrasonic)
  • SMILES
    Cc(cc(cc1)F)c1-c1c(C=CC(N2c(c(F)ccc3)c3F)=O)c2nc(NC(CO)CO)n1
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1.Singh D, et al. A randomized, placebo-controlled study of the effects of the p38 MAPK inhibitor SB-681323 on blood biomarkers of inflammation in COPD patients. J Clin Pharmacol. 2010 Jan;50(1):94-100.
molnova catalog
related products
  • LYN-1604 2HCl 221675...

    LYN-1604 is a novel ULK1 activator.It inducing cell death involved in ATF3, RAD21, and caspase3, accompanied by autophagy and apoptosis.?LYN-1604, to be the best candidate for a ULK1 agonist.?LYN-1604 induced cell death involved in ATF3, RAD21, and caspase3, accompanied by autophagy and apoptosis.?LYN-1604 has potential for good therapeutic effects on TNBC by targeting ULK1-modulated cell death in vivo.

  • ULK-101

    ULK-101 suppresses autophagy induction and autophagic flux in response to different stimuli.

  • Sofalcone

    Sofalcone a gastric antiulcer agent in clinical use is known to induce the expression of Heme oxygenase-1 (HO-1) in gastric epithelium.